Martine Piccart
Co-founded the Breast International Group and led HERA, the trial that made adjuvant trastuzumab standard.
Martine Piccart co-founded BIG and led the HERA trial of one year of adjuvant trastuzumab in HER2-positive early breast cancer; she is a past president of ESMO and of the European CanCer Organisation.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (HERA) | NEJM | 2005 |
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
Pages like this
not linked directly; found by shared links- PersonEvandro de Azambuja
Shares Institut Jules Bordet, Breast International Group (BIG), OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, HER2-positive breast cancer.
- PersonDavid Cameron
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), Breast International Group (BIG), HER2-positive breast cancer.
- PersonBarbara Bradfield
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), Trastuzumab, HER2-positive breast cancer.
- PersonSibylle Loibl
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, HER2-positive breast cancer.
- PersonCharles E. Geyer Jr.
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, HER2-positive breast cancer.
- InstitutionNSABP Foundation
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), Trastuzumab, HER2-positive breast cancer.
- InstitutionSOLTI Cancer Research Group
Shares Breast International Group (BIG), Trastuzumab, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Trastuzumab, HER2-positive breast cancer.